Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This trial is a multi-center, non-randomized, open-label Phase II study evaluating the
feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab. The
trial will enroll patients with pediatric relapsed/refractory solid tumors.